

Patient Discussion Guide

Did You Know?

Up to 30% of men with a negative prostate biopsy result actually have undetected cancer?¹

Unfortunately, today's gold standard for prostate cancer diagnosis, the biopsy procedure, provides less than a 1% sample of your entire prostate.² Prostate cancer may be present in one or more small tumors and there is a risk the biopsy needle could have missed it.

Confirm mdx tests the DNA from your previous biopsy sample to determine your risk that the needle may have missed the tumor. It requires no additional procedure and there is no out-of-pocket cost for Medicare beneficiaries.

**Print this discussion guide and take it to your next doctor's appointment.
Ask if Confirm mdx may be right for you.**



Answer This:

Have you had a prostate biopsy in the last 30 months?

- Yes No



Ask This:

- Could I have prostate cancer in areas of the prostate not biopsied?
- Is Confirm mdx right for me?



Why do I need Confirm mdx?

A standard prostate biopsy samples less than 1% of the prostate. Because the biopsy provides limited information, your provider may consider additional testing to determine your risk for undetected cancer.

Confirm mdx can provide your urologist with actionable information that helps:

- Confidently rule out prostate cancer-free men from having a potentially unnecessary invasive repeat biopsy procedure.
- Determine if you are at high risk for prostate cancer and may need a repeat biopsy and potential treatment.

Will my insurance cover Confirm mdx?

Mdxhealth will work directly with your insurance provider to coordinate coverage. The vast majority of patients are responsible for \$250 or less, and \$0 patient responsibility for Medicare.

For questions about insurance, contact our Patient Advocate Team at **(866) 259-7001**, Mon-Fri 6:00am - 4:30pm PT, or email patientfirst@mdxhealth.com.

Where can I get the Confirm mdx test?

Ask your urologist about getting the Confirm mdx test. They can request your tissue samples from your previous biopsy for testing.

No additional procedure or office visit required.


For Healthcare Providers

Confirm mdx examines biopsy tissue at a DNA level to detect cancer-related changes that cannot be seen during a standard microscopic evaluation.

Patient Eligibility

A patient with a cancer-negative prostate biopsy, including benign, HGPIN, atypical and/or ASAP histopathology findings are eligible; specimen must have been collected within 30 months from date of receipt at mdxhealth.

How it Works:



References:

¹ Aubry et al. American Health Drug and Benefits 2013;6(1):15-24.

² Ross et al. Cancer Epidemiol Biomarkers Prev 2008;17(3).

Disclaimer:

Mdxhealth is regulated under the Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) as an accredited laboratory to perform high complexity clinical testing. The Select mdx for Prostate Cancer test was developed, and its performance characteristics determined by mdxhealth. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined such clearance or approval is not necessary.

CLIA# 05D2033858; CAP# 8015399.